See Cancer In Real Time

In addition to current use in ovarian cancer,

Cytalux is Now FDA approved for use
as an adjunct in adults with lung cancer

Read the press release

CYTALUX® is the latest advancement in Intraoperative Molecular Imaging that illuminates cancer in real time.

CYTALUX is an FDA approved optical imaging agent indicated as an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer and malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung.

In clinical trials, CYTALUX detected additional ovarian and lung cancer
that wouldn’t have been detected otherwise.

0%

With CYTALUX, additional malignant lesions were found in
27% of ovarian patients.*

OVARIAN CANCER TRIAL DETAILS
0%

24% of lung cancer patients
had a Clinically Significant Event (CSE) when CYTALUX was used.^

* Women highly suspicious for or with confirmed ovarian cancer who underwent both normal and fluorescent light evaluation (Intent-to-Image set); N=134, 95% CI [19.6, 35.2]
^ Patients highly suspicious for or with confirmed cancer in the lung who underwent both normal and fluorescent light evaluation (Intent-to-Image set); N=100, 95% CI [16.0, 33.6] A CSE was defined as 1). Localization of the primary lesion that was not able to be localized with standard methods and 2). Identification of a malignant synchronous lesion that was not previously identified.

Speak with a representative
about CYTALUX and how to bring this technology to your OR.